BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Psoriasis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for psoriasis: 184 (82 sponsors; 34 newly posted in the last 180 days, 4 stopped in the last 180 days; 14 new-entrant sponsors). Momentum score 26.6, rank 9 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 22, Phase 2 38, Phase 3 62, Phase 4 11, N/A 51.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Janssen Research & Development, LLC | 16 | P2 1, P3 11, P4 2, NA 2 | 1 | 2 |
| Takeda TAK | 7 | P3 7 | 2 | 0 |
| Bristol-Myers Squibb BMY | 16 | NA 10, P3 6 | 1 | 2 |
| AbbVie ABBV | 12 | P3 4, NA 5, P2 2, P1 1 | 1 | 0 |
| UCB Biopharma SRL | 5 | P3 3, P1 2 | 0 | 1 |
| Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 3 | P3 3 | 0 | 0 |
| MoonLake Immunotherapeutics AG MLTX | 3 | P3 3 | 0 | 1 |
| Sun Pharmaceutical Industries Limited | 3 | P3 3 | 0 | 0 |
| InventisBio Co., Ltd | 4 | P3 2, P2 2 | 0 | 0 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 3 | P4 1, P3 2 | 0 | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 4 | P2 2, P1 1, P3 1 | 0 | 1 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 3 | P3 1, P1 1, P2 1 | 1 | 0 |
| Hansoh BioMedical R&D Company | 3 | P2 2, P3 1 | 1 | 2 |
| Alumis Inc ALMS | 2 | P3 1, P2 1 | 0 | 0 |
| Celltrion | 2 | NA 1, P3 1 | 0 | 1 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | 2 | P3 1, P2 1 | 0 | 1 |
| SFA Therapeutics | 2 | P3 1, P1 1 | 0 | 0 |
| Zhejiang Wenda Pharma Technology LTD. | 2 | P2 1, P3 1 | 1 | 1 |
| Beijing InnoCare Pharma Tech Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Biocad | 1 | P3 1 | 0 | 0 |
| Can-Fite BioPharma CANF | 1 | P3 1 | 0 | 0 |
| Dermavon Holdings Limited | 1 | P3 1 | 0 | 0 |
| Janssen Pharmaceutical K.K. | 1 | P3 1 | 0 | 0 |
| Psoriasis Research Institute of Guangzhou | 1 | P3 1 | 0 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
Recently stopped trials
- NCT06723171 Io Therapeutics - suspended: Sponsor request for study hold, funding issues Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
- NCT06380907 Zai Lab (Hong Kong), Ltd. - terminated: Sponsor decision A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
- NCT07314060 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. - terminated: Due to the company's strategic adjustment in product portfolio, this study has been voluntarily terminated. A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
- NCT07449234 Janssen-Cilag Ltd. - terminated: Study terminated due to insufficient enrollment. A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P3 | Zhejiang Wenda Pharma Technology LTD. | NCT07672561 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to | Moderate to Severe Plaque Psoriasis | recruiting | 375 |
| 2026-12-20 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07158268 A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | not yet recruiting | 220 |
| 2026-12-31 est. | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT07719530 Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis | Psoriasis | recruiting | 60 |
| 2027-01 est. | P3 | Reistone Biopharma Company Limited | NCT07543224 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients W | Plaque Psoriasis Subjects | not yet recruiting | 600 |
| 2027-02 est. | P2 | Clarent Biopharma, Inc. | NCT07706530 Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA) | Arthritic Psoriasis | not yet recruiting | 240 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-12-12 | PDUFA date (company-disclosed) | pending | ANAPTYSBIO, INC ANAB | imsidolimab | PDUFA Dec. 12, 2026 - ANAPTYSBIO, INC (imsidolimab) |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-06 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07150988 A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis | Psoriasis | not yet recruiting | 150 |
| 2026-11 est. | P3 | Wooshin Labottach Co., Ltd. | NCT07029516 Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis | Nail Psoriasis; Nail Damage; Mycosis | recruiting | 72 |
| 2026-10-30 | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT07251998 Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 182 |
| 2026-10-21 | P2 | Oruka Therapeutics, Inc. ORKA | NCT07290569 Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | active not recruiting | 160 |
| 2026-10-14 | P3 | Organon and Co OGN | NCT05172726 Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | Plaque Psoriasis | completed | 58 |
| 2026-09-30 est. | P3 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | NCT07265284 A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis | Psoriasis | recruiting | 104 |
| 2026-08-12 | P3 | Amgen AMGN | NCT06088199 A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis | Plaque Psoriasis | completed | 51 |
| 2026-08-06 | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07357831 A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects | Plaque Psoriasis | completed | 539 |
| 2026-07-31 est. | P2 | Clarent Biopharma, Inc. | NCT07204639 Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects | Psoriasis | recruiting | 100 |
| 2026-07-30 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT07314060 A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis | Generalized Pustular Psoriasis | terminated | 36 |
| 2026-07-21 | P3 | Bristol-Myers Squibb BMY | NCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis | Psoriasis | completed | 1466 |
| 2026-07-09 est. | P2 | Hansoh BioMedical R&D Company | NCT06926582 A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis | Psoriasis | not yet recruiting | 305 |
| 2026-07 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06833307 The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis | Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis | not yet recruiting | 90 |
| 2026-06-07 est. | P3 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | NCT06945107 A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy | Plaque Psoriasis | active not recruiting | 308 |
| 2026-06-01 est. | P2/P3 | SFA Therapeutics | NCT06863493 Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients | Psoriasis (PsO) | not yet recruiting | 125 |
| 2026-06 est. | P3 | Biocad | NCT06640517 Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | active not recruiting | 140 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "psoriasis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.